- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
GTXI Market Currents
more »
-
May 8 GTx (GTXI) +10.3% premarket after saying the FDA removed its Full Clinical Hold on its Investigational New Drug application for prostate cancer treatment Capesaris. During Q3, GTXI expects to initiate a Phase II clinical study of Capesaris as a secondary hormonal therapy in men with certain kinds of prostate cancer. (also: earnings)
Comment![Healthcare, On the Move]
GTXI Related Articles
more »
GTXI News
more »
-
at MarketWatch.com (May 8, 2012)
-
at MarketWatch.com (Feb 21, 2012)
-
at MarketWatch.com (Jan 30, 2012)
-
at MarketWatch.com (Jun 20, 2011)
-
at MarketWatch.com (Jun 8, 2011)
GTXI Press Releases and Filings
more »
-
Business Wire (May 8, 2012)
-
Business Wire (May 8, 2012)
-
Business Wire (Apr 25, 2012)
-
Business Wire (Apr 4, 2012)
GTXI Latest Transcript
more »
GTXI Cramer
more »
-
Thu, May 15, 2008
GTXI Instablog posts
more »
GTXI vs. ETF Alternatives
Company Description
GTx, Inc., a Delaware corporation incorporated on September 24, 1997, is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other... More
